Tafasitamab and lenalidomide are likely to be approved with R-CHOP for frontline DLBCL, but with bispecific antibodies on the horizon, the role of the combination is uncertain.

By Christy Santhosh May 30 (Reuters) - Incyte's Monjuvi as part of a multi-drug regimen that includes a chemotherapy standard of care for an aggressive form of non-Hodgkin lymphoma reduced the risk of ...

The two Giants teammates made their first public comments to diffuse any notion of strife between them.

Rachel, a four-month-old mixed-breed dog at the SPCA of Southwest Michigan, is hoping to find her forever home.

A dad-of-four who was told his agonising leg pain was sciatica has died after his symptoms turned out to be signs of an aggressive cancer. Joe Till, 33, repeatedly visited walk-in centres complaining ...

Joe Till's family said he "fought with incredible strength and courage right until the very end" ...

Outcomes for patients with high-risk large B-cell lymphoma (LBCL), defined by an International Prognostic Index (IPI) score ...

After Thomas Saggese homered on Friday at Busch Stadium, the Cardinals' "Tarps Off" fans went wild.  Sports columnist {{description}} Email notifications are only sent once a day, and only if there ...